Hugel, a leading South Korean medical aesthetics company, is set to accelerate growth in the second half of the year through a dual US direct sales strategy and the launch of its ECM skin booster Cellrderm. This move signals expanded opportunities for overseas distributors and clinics seeking high-quality toxin, filler, and skin booster products from a globally integrated supplier.
US Direct Sales and Market Share Targets
Hugel entered the US market in March 2025 and secured approximately 3% market share in its first year. Starting in the second half of 2025, the company will supplement its existing indirect sales through distribution partners with a direct sales organization. This shift is expected to internalize distribution margins, improve pricing control, and accelerate market penetration.
Hugel targets expanding its US market share from 3% in 2025 to 5% in 2026, 10% in 2028, and 14% by 2030. The US toxin market accounts for about half of the global market and offers average selling prices 3–5 times higher than in South Korea, making it a key growth driver.
Global Market Expansion and Strategy
Hugel is the only company to have entered all four major global toxin markets—the US, China, Europe, and Brazil—which together represent 80% of the global market. In China, the company benefits from the "one patient, one vial" policy, which drives demand for its 50-unit product, the only such approval held by a Korean firm. Hugel held a 22% market share in China in 2025.
In Brazil, Hugel re-entered the market in September 2025 through a new agreement with local distributor Derma Dream under the "Letibo" brand. In Europe, the company is strengthening medical marketing based on Narrow Diffusion clinical data.
Cellrderm Skin Booster Launch and Portfolio Expansion
Hugel will begin domestic distribution of the ECM skin booster Cellrderm in July, under a co-promotion structure with a minimum order quantity of about 10,000 units per month. Distribution revenue is estimated at around KRW 1.5 billion per quarter, but the company expects additional bundling effects with its existing toxin and filler sales network.
Overseas, Hugel has secured global exclusive rights to human-derived synthetic collagen-based products through collaboration with US biotech Gelatec. The company plans to expand its skin booster lineup—including ECM, synthetic collagen, and PLA—via licensing, business development, and M&A.
Financial Outlook and Analyst View
Shinhan Securities forecasts Hugel's 2026 revenue at KRW 523.8 billion (up 23.2% YoY) and operating profit at KRW 217.9 billion (up 8.5% YoY), with an operating margin of 41.6%. The report notes that short-term profitability may have bottomed out due to upfront investments in US direct sales and medical marketing, but revenue leverage is expected to improve from Q3 2025.
The analyst maintains a "Buy" rating with a target price of KRW 350,000, implying a 53.5% upside from the June 8 closing price.
What Buyers Should Watch
For overseas importers and distributors, Hugel's dual US sales channel and expanding skin booster portfolio present new sourcing opportunities. The company's strong position in China and re-entry into Brazil also signal reliable supply chains for high-demand toxin and filler products. Clinics and buyers should monitor Hugel's bundling strategies and new product launches, which may offer competitive pricing and integrated solutions.
Source: Read the original report | Published: June 09, 2026